---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-322950"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2025-12-17T23:59:59+00:00"
generated_at: "2026-05-16T12:56:08.979619+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kalaris Therapeutics reports positive Phase 1a data for TH103 in nAMD; accelerates development

## Summary
- Mean 10-letter BCVA gain and 129 µm CST improvement at Month 1 across all dose levels (0.5–2.5 mg).
- Mean ~95% reduction in central subfield intraretinal fluid; no dose-limiting toxicities or TH103-related serious AEs.
- Two transient IOI cases at 2.5 mg resolved with manufacturing process change; zero new IOI in 6 subsequent subjects.
- 31% of patients (4/13) required no additional anti-VEGF treatment during the 6-month follow-up after a single injection.
- Plasma Cmax 27–51-fold lower vs. leading anti-VEGF agents; Phase 1b/2 enrollment ongoing, preliminary data expected 2H 2026.

## SEC filing metadata
- accession: 0001193125-25-322950
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2025-12-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312525322950/0001193125-25-322950-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312525322950/d25416d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-322950
- JSON: https://secwatch.observer/filing/0001193125-25-322950.json
- Plain text: https://secwatch.observer/filing/0001193125-25-322950.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.